Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico
Fluoxetine has been the first antidepressive agent of the class of selective serotonine reuptake inhibitors (SSRI) to be introduced in therapy, back in 1987. The availability of SSRIs has meant a great advance in the treatment of major depression and other neuro-psychiatric pathologies. In this pape...
Main Authors: | Carlo Della Pepa, Mario Eandi |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd Medical Publishers
2003-09-01
|
Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/775 |
Similar Items
-
Profilo terapeutico e farmacoeconomico di linezolid
by: Mario Eandi
Published: (2004-06-01) -
Moxifloxacina: profilo farmacologico, terapeutico e farmacoeconomico
by: Mario Eandi
Published: (2003-06-01) -
Mesalazina: profilo farmacologico, terapeutico e farmacoeconomico
by: Mario Eandi, et al.
Published: (2003-12-01) -
Tramadolo: profilo farmacologico, terapeutico e farmacoeconomico
by: Loredana Serpe, et al.
Published: (2004-09-01) -
Fluvoxamina: profilo farmacoeconomico
by: Mario Eandi
Published: (2001-09-01)